190 related articles for article (PubMed ID: 29563798)
1. Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy.
Duan X; Mu M; Yan J; Bai L; Zhong L; Zhu Y; Pan H; Zhang M; Shi J
Int J Nanomedicine; 2018; 13():1443-1456. PubMed ID: 29563798
[TBL] [Abstract][Full Text] [Related]
2. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
Mu P; Nagahara S; Makita N; Tarumi Y; Kadomatsu K; Takei Y
Int J Cancer; 2009 Dec; 125(12):2978-90. PubMed ID: 19422046
[TBL] [Abstract][Full Text] [Related]
3. Effective Skin Cancer Treatment by Topical Co-delivery of Curcumin and STAT3 siRNA Using Cationic Liposomes.
Jose A; Labala S; Ninave KM; Gade SK; Venuganti VVK
AAPS PharmSciTech; 2018 Jan; 19(1):166-175. PubMed ID: 28639178
[TBL] [Abstract][Full Text] [Related]
4. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy.
Zheng C; Zheng M; Gong P; Deng J; Yi H; Zhang P; Zhang Y; Liu P; Ma Y; Cai L
Biomaterials; 2013 Apr; 34(13):3431-8. PubMed ID: 23375952
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid
Li W; Yan R; Liu Y; He C; Zhang X; Lu Y; Khan MW; Xu C; Yang T; Xiang G
Drug Deliv; 2019 Dec; 26(1):794-802. PubMed ID: 31366257
[TBL] [Abstract][Full Text] [Related]
6. Insights into the therapeutic potential of hypoxia-inducible factor-1α small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes.
Chen Z; Zhang T; Wu B; Zhang X
Int J Nanomedicine; 2016; 11():991-1002. PubMed ID: 27042054
[TBL] [Abstract][Full Text] [Related]
7. Aurora B Inhibitor TAK-901 Synergizes with BCL-xL Inhibition by Inducing Active BAX in Cancer Cells.
Murai S; Matuszkiewicz J; Okuzono Y; Miya H; DE Jong R
Anticancer Res; 2017 Feb; 37(2):437-444. PubMed ID: 28179288
[TBL] [Abstract][Full Text] [Related]
8. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.
Yao Y; Su Z; Liang Y; Zhang N
Int J Nanomedicine; 2015; 10():6185-97. PubMed ID: 26491291
[TBL] [Abstract][Full Text] [Related]
9. Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes.
Hemati M; Haghiralsadat F; Jafary F; Moosavizadeh S; Moradi A
Int J Nanomedicine; 2019; 14():6575-6585. PubMed ID: 31616144
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth.
Guruprasath P; Kim J; Gunassekaran GR; Chi L; Kim S; Park RW; Kim SH; Baek MC; Bae SM; Kim SY; Kim DK; Park IK; Kim WJ; Lee B
Biomaterials; 2017 Oct; 142():101-111. PubMed ID: 28732245
[TBL] [Abstract][Full Text] [Related]
11. siRNA-mediated Bcl-2 and Bcl-xl gene silencing sensitizes human hepatoblastoma cells to chemotherapeutic drugs.
Lei XY; Zhong M; Feng LF; Zhu BY; Tang SS; Liao DF
Clin Exp Pharmacol Physiol; 2007; 34(5-6):450-6. PubMed ID: 17439414
[TBL] [Abstract][Full Text] [Related]
12. Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy.
Kunze D; Erdmann K; Froehner M; Wirth MP; Fuessel S
Int J Mol Sci; 2013 Jun; 14(6):12297-312. PubMed ID: 23749114
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of curcumin and STAT3 siRNA using deformable cationic liposomes to treat skin cancer.
Jose A; Labala S; Venuganti VV
J Drug Target; 2017 Apr; 25(4):330-341. PubMed ID: 27819148
[TBL] [Abstract][Full Text] [Related]
14. Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy.
Kang SH; Cho HJ; Shim G; Lee S; Kim SH; Choi HG; Kim CW; Oh YK
Pharm Res; 2011 Dec; 28(12):3069-78. PubMed ID: 21879387
[TBL] [Abstract][Full Text] [Related]
15. Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Huang K; Chen X; Zhang Z; He Q
Int J Pharm; 2014 Dec; 477(1-2):590-600. PubMed ID: 25448564
[TBL] [Abstract][Full Text] [Related]
16. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer.
Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT
Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252
[TBL] [Abstract][Full Text] [Related]
17. Cationic liposomes co-deliver chemotherapeutics and siRNA for the treatment of breast cancer.
Li M; Li S; Li Y; Li X; Yang G; Li M; Xie Y; Su W; Wu J; Jia L; Li S; Ma W; Li H; Guo N; Yu P
Eur J Med Chem; 2022 Apr; 233():114198. PubMed ID: 35245829
[TBL] [Abstract][Full Text] [Related]
18. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
19. Rapid delivery of small interfering RNA by biosurfactant MEL-A-containing liposomes.
Inoh Y; Furuno T; Hirashima N; Kitamoto D; Nakanishi M
Biochem Biophys Res Commun; 2011 Oct; 414(3):635-40. PubMed ID: 22001930
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles.
Kim JS; Kim MW; Kang SJ; Jeong HY; Park SI; Lee YK; Kim HS; Kim KS; Park YS
Int J Nanomedicine; 2018; 13():4817-4830. PubMed ID: 30214190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
